Please login to the form below

Not currently logged in
Email:
Password:

type 2 diabetes

This page shows the latest type 2 diabetes news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

Could help revival after amputation risk scare. Johnson &Johnson's diabetes drug Invokana has shown it can slow down kidney disease or even prevent it all together. ... Results from the CREDENCE study, which evaluated type 2 diabetes patients with

Latest news

  • NICE recommends MSD’s diabetes drug Steglatro NICE recommends MSD’s diabetes drug Steglatro

    NICE has cleared MSD’s type 2 diabetes treatment Steglatro for routine NHS use in combination with metformin, or as a monotherapy for those who are intolerant to the anti-diabetic ... drug. Steglatro is one of the competitors in the sodium-glucose

  • Novo uses voucher for speedy answer on oral semaglutide Novo uses voucher for speedy answer on oral semaglutide

    Novo's submission for oral semaglutide for the treatment of glycaemic control in adults with type 2 diabetes is based on the results from 10 Pioneer clinical trials, which included more ... Achieving glycaemic control and managing cardiovascular risk

  • 23andMe to offer type 2 diabetes testing kit 23andMe to offer type 2 diabetes testing kit

    New report is powered by data from the company’s customers. Personal genomics company 23andMe is now offering an at home kit to test the risk for type 2 diabetes, despite ... Using this data, scientists have developed a polygenic score that drew on

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    AZ claims first with Forxiga in type 1 diabetes. Among the usual crop of line extensions, AZ’s SGLT2 inhibitor Forxiga (dapagliflozin) became the first oral add-on treatment to insulin ... for treatment of certain patients with type 1 diabetes, adding

  • FDA adcomm split on Sanofi’s type 1 diabetes drug FDA adcomm split on Sanofi’s type 1 diabetes drug

    Current SGLT2-selective drugs – such as Johnson &Johnson’s Invokana, Eli Lilly/Boehringer Ingelheim's Jardiance and Farxiga from AstraZeneca – are approved only for type 2 diabetes. ... According to Lexicon, sotagliflozin is also being tested in

More from news
Approximately 31 fully matching, plus 422 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 5 fully matching, plus 38 partially matching documents found.

Latest appointments

  • Roche’s Torsten Hoffmann to join Zealand Pharma Roche’s Torsten Hoffmann to join Zealand Pharma

    In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity. ... Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2 ... diabetes. Ben Blackmore, bmore creative's MD, told The Directory: "We are

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics